• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三氮唑并吲唑类和三氮唑并吡嗪吡啶类化合物的设计、合成及细胞毒性活性。

Triazenoindazoles and triazenopyrazolopyridines: design, synthesis, and cytotoxic activity.

机构信息

Pharmaceutical Organic Chemistry Department, Cairo University, Cairo, 11562, Egypt.

出版信息

Arch Pharm Res. 2010 Jun;33(6):813-9. doi: 10.1007/s12272-010-0603-9. Epub 2010 Jul 6.

DOI:10.1007/s12272-010-0603-9
PMID:20607485
Abstract

Several triazenoindazoles 3a-e and triazinopyrazolopyridines 6a-i were prepared through the reaction of the corresponding 3-amino-4-chloroindazole and 3-aminopyrazolopyridine diazonium salts 2 and 5 with a number of secondary amines. All compounds were evaluated for their in vitro cytotoxic activity on three cell lines, HepG2, MCF7, and HeLa. Most compounds inhibited cell growth with IC(50) less than 0.1 microM. Compound 6d was the most potent, with an IC(50) of 0.03 microM against HepG2 and 0.05 microM against MCF7 and HeLa cells.

摘要

通过将相应的 3-氨基-4-氯吲唑和 3-氨基吡唑并吡啶重氮盐 2 和 5 与多种仲胺反应,制备了几种三唑并吲唑 3a-e 和三嗪并吡唑吡啶 6a-i。所有化合物均在三种细胞系 HepG2、MCF7 和 HeLa 上评估了其体外细胞毒性活性。大多数化合物的 IC50 小于 0.1 μM,抑制细胞生长。化合物 6d 对 HepG2 的 IC50 为 0.03 μM,对 MCF7 和 HeLa 的 IC50 为 0.05 μM,活性最强。

相似文献

1
Triazenoindazoles and triazenopyrazolopyridines: design, synthesis, and cytotoxic activity.三氮唑并吲唑类和三氮唑并吡嗪吡啶类化合物的设计、合成及细胞毒性活性。
Arch Pharm Res. 2010 Jun;33(6):813-9. doi: 10.1007/s12272-010-0603-9. Epub 2010 Jul 6.
2
Synthesis and antiproliferative activity of triazenoindazoles and triazenopyrazoles: a comparative study.三氮烯吲唑和三氮烯吡唑的合成及其抗增殖活性:一项比较研究。
Eur J Med Chem. 2004 Mar;39(3):219-24. doi: 10.1016/j.ejmech.2003.11.012.
3
Antitumor agents. 3. Design, synthesis, and biological evaluation of new pyridoisoquinolindione and dihydrothienoquinolindione derivatives with potent cytotoxic activity.抗肿瘤剂。3. 具有强细胞毒性活性的新型吡啶并异喹啉二酮和二氢噻吩并喹啉二酮衍生物的设计、合成及生物学评价。
J Med Chem. 2004 Feb 12;47(4):849-58. doi: 10.1021/jm030918b.
4
Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure-activity relationship.用于选择性靶向表皮生长因子受体过表达实体瘤的新型氮芥武装组合分子:一种不寻常构效关系的发现
J Med Chem. 2007 May 31;50(11):2605-8. doi: 10.1021/jm070144p. Epub 2007 May 2.
5
Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders.含抗肿瘤药物CC - 1065的烷基化环丙基吡咯并吲哚(CPI)亚基的两种吡唑类似物与聚吡咯小沟结合剂的水溶性杂合分子的设计、合成、DNA结合及生物学评价
J Med Chem. 2001 Aug 2;44(16):2536-43. doi: 10.1021/jm0108404.
6
Modulating effect of new potential antimelanomic agents, spin-labeled triazenes and nitrosoureas on the DOPA-oxidase activity of tyrosinase.新型潜在抗黑素瘤药物、自旋标记三氮烯和亚硝基脲对酪氨酸酶多巴氧化酶活性的调节作用
Cancer Biochem Biophys. 1999 Jul;17(1-2):99-108.
7
Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor cells.具有对顺铂耐药肿瘤细胞强细胞毒性活性的新型氯乙氨基蒽醌的合成与生物学评价
J Med Chem. 2004 Mar 25;47(7):1856-9. doi: 10.1021/jm031070u.
8
Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept.一种旨在释放多种表皮生长因子受体酪氨酸激酶抑制剂和一种烷基化剂的前药的合成:一种新型肿瘤靶向概念。
J Med Chem. 2003 Dec 4;46(25):5546-51. doi: 10.1021/jm030423m.
9
Design, synthesis and antitumor cytotoxicity of novel bis-benzimidazoles.新型双苯并咪唑的设计、合成与抗肿瘤细胞毒性
Anticancer Drug Des. 2000 Aug;15(4):265-75.
10
Anticancer activity of novel indenopyridine derivatives.新型吲哚吡啶衍生物的抗癌活性。
Arch Pharm Res. 2012 Jun;35(6):987-94. doi: 10.1007/s12272-012-0605-x. Epub 2012 Jun 30.